Skip to main content

Table 1 Statistical analysis of delta changes of cholesterol and apolipoprotein subclasses in liraglutide- and placebo-treated individuals

From: Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial

Cholesterol

Placebo

Liraglutide

P1

P2

Visit 1

Visit 6

Delta changes

Visit 1

Visit 6

Delta changes

Total chol.

3.51 ± 0.78

3.69 ± 0.82

0.18 ± 0.09

3.44 ± 0.77

3.28 ± 0.73

− 0.17 ± 0.12

0.01

0.008

Free chol.

1.08 ± 0.24

1.13 ± 0.25

0.05 ± 0.02

1.06 ± 0.24

1.01 ± 0.23

− 0.05 ± 0.03

0.01

0.01

Remnant chol.

1.14 ± 0.26

1.24 ± 0.28

0.1 ± 0.04

1.11 ± 0.25

1.09 ± 0.24

− 0.03 ± 0.04

0.01

0.02

VLDL chol.

0.58 ± 0.13

0.64 ± 0.14

0.07 ± 0.02

0.55 ± 0.12

0.56 ± 0.13

0.01 ± 0.02

0.05

0.16

LDL chol.

1.35 ± 0.3

1.39 ± 0.31

− 0.04 ± 0.11

1.34 ± 0.3

1.24 ± 0.28

− 0.09 ± 0.06

0.62

0.57

HDL chol.

1.01 ± 0.22

1 ± 0.22

− 0.005 ± 0.02

0.99 ± 0.22

0.95 ± 0.21

− 0.05 ± 0.03

0.22

0.06

HDL2 chol.

0.55 ± 0.12

0.51 ± 0.11

− 0.06 ± 0.05

0.53 ± 0.12

0.5 ± 0.11

− 0.03 ± 0.02

0.61

0.91

HDL3-C (× 10−2)

46.2 ± 10.3

46.2 ± 10.3

0.02 ± 0.3

46.2 ± 10.3

44.9 ± 10

− 1.31 ± 0.39

0.01

0.01

Est. Chol.

2.43 ± 0.54

2.5 ± 0.56

− 0.06 ± 0.17

2.38 ± 0.53

2.27 ± 0.51

− 0.12 ± 0.09

0.73

0.72

Serum-TG

1.09 ± 0.24

1.07 ± 0.24

− 0.13 ± 0.11

1 ± 0.22

1.03 ± 0.23

0.02 ± 0.03

0.19

0.32

VLDL-TG

0.73 ± 0.16

0.71 ± 0.16

− 0.09 ± 0.08

0.66 ± 0.15

0.69 ± 0.16

0.03 ± 0.03

0.15

0.24

LDL-TG (× 10−2)

14.8 ± 3.3

14.9 ± 3.32

0.06 ± 0.44

14.1 ± 3.15

13.2 ± 2.96

− 0.87 ± 0.38

0.16

0.12

HDL-TG (× 10−2)

11.2 ± 2.5

11.9 ± 2.66

0.7 ± 0.41

10.7 ± 2.39

10.8 ± 2.41

0.12 ± 0.38

0.29

0.56

TotPG

1.42 ± 0.32

1.47 ± 0.33

0.05 ± 0.04

1.35 ± 0.3

1.34 ± 0.3

− 0.02 ± 0.04

0.22

0.21

PC

1.36 ± 0.3

1.42 ± 0.31

0.06 ± 0.03

1.3 ± 0.29

1.29 ± 0.29

− 0.01 ± 0.04

0.19

0.14

SM

0.43 ± 0.1

0.45 ± 0.1

0.01 ± 0.01

0.43 ± 0.1

0.41 ± 0.09

− 0.02 ± 0.01

0.03

0.01

TotCho

1.79 ± 0.4

1.84 ± 0.41

0.05 ± 0.04

1.73 ± 0.39

1.7 ± 0.38

− 0.03 ± 0.04

0.18

0.12

Apolipoproteins

 ApoA1 (g/L)

1.18 ± 0.26

1.2 ± 0.27

0.02 ± 0.01

1.17 ± 0.26

1.14 ± 0.26

− 0.03 ± 0.02

0.08

0.04

 ApoB (g/L)

0.76 ± 0.17

0.81 ± 0.18

0.04 ± 0.02

0.74 ± 0.17

0.73 ± 0.16

− 0.02 ± 0.02

0.01

0.02

 ApoB/ApoA1 (× 102)

65.3 ± 14.6

67.6 ± 15.2

2.35 ± 1.2

64.4 ± 14.4

64.1 ± 14.3

− 0.29 ± 1.04

0.05

0.21

  1. Values are given in mmol/L. P1—Delta statistics unadjusted. P2—Delta changes adjusted for weight change. Values are reported as mean ± SE. On treatment analysis was performed for all variables. The level of significance was set to p-value < 0.05 after Bonferroni correction. Baseline samples were collected at visit 1, post treatment samples were collected at visit 6
  2. Total chol serum total cholesterol, VLDL-C total cholesterol in VLDL, Remnant chol remnant cholesterol (non-HDL, non-LDL -cholesterol), LDL chol total cholesterol in LDL, HDL chol total cholesterol in HDL, HDL2-C total cholesterol in HDL2, HDL3-C total cholesterol in HDL3, EstC Esterified cholesterol, FreeC free cholesterol, Serum-TG serum total triglycerides, VLDL-TG triglycerides in VLDL, LDL-TG triglycerides in LDL, HDL-TG triglycerides in HDL, TotPG total phosphoglycerides, PC phosphatidylcholine and other cholines, SM sphingomyelins, TotCho total cholines, ApoA1 apolipoprotein A-I, ApoB apolipoprotein B, ApoB/ApoA1 ratio of apolipoprotein B to apolipoprotein A-I
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840